Figure 3
From: Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells
p65 translocation in MCF-7 cells after the treatment of DOX and PTX. (A) Western blotting and (B) nuclear:cytoplasmic ratio of NF-κB p65 in cytoplasmic and nuclear fractions of DOX and PTX treated MCF-7 cells at 0, 0.5, 1, 2, 4, 8 h. (C) Western blotting of NF-κB p65 after 2 h treatment of DOX and PTX using Actin and TBP as loading controls. (D) A quantitative analysis of nuclear:cytoplasmic ratio of p65 in (C). *, p < 0.05; **, p < 0.01; ***, p < 0.001 (n = 3).